Westhouse Securities Reiterates “Buy” Rating for Advanced Oncotherapy PLC (AVO)
Advanced Oncotherapy PLC (LON:AVO)‘s stock had its “buy” rating restated by analysts at Westhouse Securities in a research report issued to clients and investors on Thursday. They currently have a GBX 9 ($0.15) price target on the stock. Westhouse Securities’ price objective points to a potential upside of 147.93% from the company’s current price.
AVO has been the subject of a number of other recent research reports. Analysts at Beaufort Securities reiterated a “speculative buy” rating on shares of Advanced Oncotherapy PLC in a research note on Monday.
Advanced Oncotherapy PLC (LON:AVO) traded up 1.64% on Thursday, hitting GBX 3.71. The stock had a trading volume of 1,005,746 shares. Advanced Oncotherapy PLC has a 52 week low of GBX 2.40 and a 52 week high of GBX 4.00. The stock’s 50-day moving average is GBX 3.27 and its 200-day moving average is GBX 2.96.
Advanced Oncotherapy PLC is a United Kingdom-based specialist developer and provider of the particle therapy systems with protons that makes radiation less toxic for patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.